Can radiomics signatures predict tumor reponse of patients treated with chemotherapy and targeted therapy?

The authors of this retrospective study had the goal of evaluating the effectiveness of radiomics signatures in order to predict the tumor response of non-small cell lung cancer (NSCLC) patients who were treated with first-line chemotherapy, targeted therapy, or a combination of the two. The authors determined that radiomics signatures based on pre-treatment CT scans can accurately predict tumor response in NSCLC patients after first-line chemotherapy and/or targeted therapy treatments and have a promising future as prognostic imaging biomarkers.

Key points

• The radiomics signature extracted from baseline CT images in patients with NSCLC can predict response to first-line chemotherapy, targeted therapy, or both treatments with an AUC = 0.746 (95% CI, 0.646–0.846).
• The radiomics signature could be used as a new biomarker for quantitative analysis in radiology, which might provide value in decision-making and to define personalized treatments for cancer patients.

Article: CT-based radiomics signatures can predict the tumor response of non-small cell lung cancer patients treated with first-line chemotherapy and targeted therapy

Authors: Fengchang Yang, Jiayi Zhang, Liu Zhou, Wei Xia, Rui Zhang, Haifeng Wei, Jinxue Feng, Xingyu Zhao, Junming Jian, Xin Gao & Shuanghu Yuan